Genenta Science S.p.A. has received a notification from Nasdaq indicating that it is not in compliance with the minimum bid price requirement. This notification comes as the company's American Depositary Shares (ADSs) have traded below $1.00 for 30 consecutive business days. The situation is significant as it may impact the company's listing status on the Nasdaq Capital Market.

On October 16, 2026, Genenta received the notification letter from Nasdaq's Listing Qualifications Department. The company has been granted an initial compliance period of 180 calendar days, until April 14, 2027, to regain compliance. During this period, the closing bid price of the ADSs must be at least $1.00 for a minimum of 10 consecutive business days.

Background

Genenta Science S.p.A. is a biotechnology firm based in Milan, Italy, that focuses on biological products, specifically in the area of gene therapy. The company trades on the Nasdaq under the ticker symbol GNTA. It has been classified under the SIC code 2836, which pertains to biological products, excluding diagnostic substances. Recent filings indicate that the company has been active in providing updates to its shareholders about its business operations and compliance status.

What the Filing Says

The filing states that "the notification does not result in the immediate delisting of the Company’s ADSs, which will continue to trade on the Nasdaq Capital Market under the symbol 'GNTA.'" It also outlines that Genenta may be eligible for an additional compliance period if it does not regain compliance by the deadline.

Impact

This situation may affect the company’s shareholders and investors, as the compliance issue could influence the trading of its ADSs. Additionally, it may impact the company’s strategic decisions moving forward, including the potential implementation of a reverse stock split, which has already been approved by shareholders.

What's Next

Genenta intends to monitor its ADSs closely and evaluate options to regain compliance with Nasdaq’s minimum bid price requirement. The company has not specified further actions beyond this compliance period in the filing.